ARTICLE
Effect of selenium as an adjunctive therapy
in patients with treatment-resistant
obsessive-compulsive disorder:
A pilot randomized double blind
placebo-controlled clinical trial
| 1 | jundishpour University |
CORRESPONDING AUTHOR
Submission date: 2018-07-03
Final revision date: 2018-11-03
Acceptance date: 2018-11-05
Publication date: 2018-12-12
Arch Psych Psych 2018;20(4):57–65
KEYWORDS
TOPICS
ABSTRACT
Aim of the study:
The first line medicinal treatment of Obsessive Compulsive Disorder includes Selective Serotonin Reuptake Inhibitors (SSRIs).Researchers have shown that there is a correlation between the trace elements deficiency such as selenium and mental disorders and mood, since selenium is a safe and non-tolerable side-effect supplementation that may be useful as an adjunctive treatment with SSRIs.
Subject or material and methods:
Thirty-two patients with a treatment-resistant obsessive-compulsive disorder were selected and randomly entered into two groups: intervention and control, while both groups continued to consume SSRI drugs according to the current procedure. The intervention group received one 200 mcg selenium capsule daily and each daily control group received one capsule of placebo for 6 weeks.
Results:
Y-BOCS scores decreased at the end of the sixth week in both groups, but this reduction was significantly lower in the selenium group (P = 0.01). Selenium was well tolerated and there was no significant difference between the two groups in the incidence of side effects
Discussion:
The results of this study indicate that selenium as an adjunctive treatment with SSRIs improves symptoms
Conclusions:
Selenium can be as new drug for treatment of Refractory OCD.
The first line medicinal treatment of Obsessive Compulsive Disorder includes Selective Serotonin Reuptake Inhibitors (SSRIs).Researchers have shown that there is a correlation between the trace elements deficiency such as selenium and mental disorders and mood, since selenium is a safe and non-tolerable side-effect supplementation that may be useful as an adjunctive treatment with SSRIs.
Subject or material and methods:
Thirty-two patients with a treatment-resistant obsessive-compulsive disorder were selected and randomly entered into two groups: intervention and control, while both groups continued to consume SSRI drugs according to the current procedure. The intervention group received one 200 mcg selenium capsule daily and each daily control group received one capsule of placebo for 6 weeks.
Results:
Y-BOCS scores decreased at the end of the sixth week in both groups, but this reduction was significantly lower in the selenium group (P = 0.01). Selenium was well tolerated and there was no significant difference between the two groups in the incidence of side effects
Discussion:
The results of this study indicate that selenium as an adjunctive treatment with SSRIs improves symptoms
Conclusions:
Selenium can be as new drug for treatment of Refractory OCD.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.